By Ilan Zipkin
Staff Writer

CoCensys Inc. continues to hunt for clinical and business strategies to keep the company alive despite failing to achieve the positive clinical data that would have signaled a change in its fortunes. COCN last week announced that much-anticipated Phase II data for its CCD 1042 ganaxolone epalon GABA receptor modulator in acute migraine did not reach statistical significance.